Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial

医学 血压 去神经支配 动态血压 抗高血压药 回廊的 临床终点 人口 临床试验 麻醉 随机对照试验 内科学 心脏病学 泌尿科 外科
作者
Felix Mahfoud,David E Kandzari,Kazuomi Kario,Raymond R Townsend,Michael A Weber,Roland E Schmieder,Konstantinos Tsioufis,Stuart Pocock,Kyriakos Dimitriadis,James W Choi,Cara East,Richard D'Souza,Andrew S P Sharp,Sebastian Ewen,Antony Walton,Ingrid Hopper,Sandeep Brar,Pamela McKenna,Martin Fahy,Michael Böhm
出处
期刊:The Lancet [Elsevier]
卷期号:399 (10333): 1401-1410 被引量:7
标识
DOI:10.1016/s0140-6736(22)00455-x
摘要

Summary

Background

Renal denervation has been shown to lower blood pressure in the presence of antihypertensive medications; however, long-term safety and efficacy data from randomised trials of renal denervation are lacking. In this pre-specified analysis of the SPYRAL HTN-ON MED study, we compared changes in blood pressure, antihypertensive drug use, and safety up to 36 months in renal denervation versus a sham control group.

Methods

This randomised, single-blind, sham-controlled trial enrolled patients from 25 clinical centres in the USA, Germany, Japan, the UK, Australia, Austria, and Greece, with uncontrolled hypertension and office systolic blood pressure between 150 mm Hg and 180 mm Hg and diastolic blood pressure of 90 mm Hg or higher. Eligible patients had to have 24-h ambulatory systolic blood pressure between 140 mm Hg and less than 170 mm Hg, while taking one to three antihypertensive drugs with stable doses for at least 6 weeks. Patients underwent renal angiography and were randomly assigned (1:1) to radiofrequency renal denervation or a sham control procedure. Patients and physicians were unmasked after 12-month follow-up and sham control patients could cross over after 12-month follow-up completion. The primary endpoint was the treatment difference in mean 24-h systolic blood pressure at 6 months between the renal denervation group and the sham control group. Statistical analyses were done on the intention-to-treat population. Long-term efficacy was assessed using ambulatory and office blood pressure measurements up to 36 months. Drug surveillance was used to assess medication use. Safety events were assessed up to 36 months. This trial is registered with ClinicalTrials.gov, NCT02439775; prospectively, an additional 260 patients are currently being randomly assigned as part of the SPYRAL HTN-ON MED Expansion trial.

Findings

Between July 22, 2015, and June 14, 2017, among 467 enrolled patients, 80 patients fulfilled the qualifying criteria and were randomly assigned to undergo renal denervation (n=38) or a sham control procedure (n=42). Mean ambulatory systolic and diastolic blood pressure were significantly reduced from baseline in the renal denervation group, and were significantly lower than the sham control group at 24 and 36 months, despite a similar treatment intensity of antihypertensive drugs. The medication burden at 36 months was 2·13 medications (SD 1·15) in the renal denervation group and 2·55 medications (2·19) in the sham control group (p=0·26). 24 (77%) of 31 patients in the renal denervation group and 25 (93%) of 27 patients in the sham control group adhered to medication at 36 months. At 36 months, the ambulatory systolic blood pressure reduction was −18·7 mm Hg (SD 12·4) for the renal denervation group (n=30) and −8·6 mm Hg (14·6) for the sham control group (n=32; adjusted treatment difference −10·0 mm Hg, 95% CI −16·6 to −3·3; p=0·0039). Treatment differences between the renal denervation group and sham control group at 36 months were −5·9 mm Hg (95% CI −10·1 to −1·8; p=0·0055) for mean ambulatory diastolic blood pressure, −11·0 mm Hg (−19·8 to −2·1; p=0·016) for morning systolic blood pressure, and −11·8 mm Hg (−19·0 to −4·7; p=0·0017) for night-time systolic blood pressure. There were no short-term or long-term safety issues associated with renal denervation.

Interpretation

Radiofrequency renal denervation compared with sham control produced a clinically meaningful and lasting blood pressure reduction up to 36 months of follow-up, independent of concomitant antihypertensive medications and without major safety events. Renal denervation could provide an adjunctive treatment modality in the management of patients with hypertension.

Funding

Medtronic.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
南风完成签到 ,获得积分10
1秒前
浠苒完成签到 ,获得积分10
7秒前
小学生完成签到,获得积分10
8秒前
原点完成签到 ,获得积分10
22秒前
困困困完成签到 ,获得积分10
24秒前
廉洁完成签到,获得积分10
26秒前
阡陌完成签到,获得积分10
31秒前
单薄广山完成签到,获得积分10
34秒前
123完成签到 ,获得积分10
38秒前
肉肉完成签到 ,获得积分10
40秒前
爱学习的小白完成签到 ,获得积分10
46秒前
51秒前
PV YTT完成签到,获得积分10
54秒前
曾建完成签到 ,获得积分10
54秒前
八乙基环辛四烯完成签到,获得积分10
1分钟前
1分钟前
benben应助科研通管家采纳,获得10
1分钟前
猫沫沫829发布了新的文献求助10
1分钟前
matilda完成签到 ,获得积分10
1分钟前
小白完成签到 ,获得积分10
1分钟前
ANT完成签到 ,获得积分10
1分钟前
AHA完成签到,获得积分10
1分钟前
1分钟前
思源应助juphen2采纳,获得10
1分钟前
1分钟前
娜娜子完成签到 ,获得积分10
1分钟前
1分钟前
AthenaWang完成签到 ,获得积分10
1分钟前
十二完成签到,获得积分10
1分钟前
xgx984完成签到,获得积分10
1分钟前
欢喜的慕青完成签到 ,获得积分10
1分钟前
蔡从安完成签到,获得积分20
1分钟前
科里斯皮尔应助蔡从安采纳,获得20
1分钟前
星辰大海应助蔡从安采纳,获得10
1分钟前
绿袖子完成签到,获得积分10
1分钟前
北辰完成签到 ,获得积分10
1分钟前
细心的雅绿完成签到 ,获得积分10
1分钟前
虚幻元风完成签到 ,获得积分10
2分钟前
踏实的无敌完成签到,获得积分10
2分钟前
2分钟前
高分求助中
请在求助之前详细阅读求助说明!!!! 20000
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 1500
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
The Three Stars Each: The Astrolabes and Related Texts 500
A radiographic standard of reference for the growing knee 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2468888
求助须知:如何正确求助?哪些是违规求助? 2136196
关于积分的说明 5442921
捐赠科研通 1860798
什么是DOI,文献DOI怎么找? 925473
版权声明 562694
科研通“疑难数据库(出版商)”最低求助积分说明 495093